Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Sankyo Looks At Consolidating Stake In Zenotech; Minority Shareholders, Founder Cry Hoarse

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Daiichi Sankyo, the majority equity holder in India's largest drug company Ranbaxy, has encountered a hurdle in its proposal to make an open offer for 20 percent shares in Zenotech Labs. Shareholders of Zenotech Labs have pleaded that the open offer price fixed by Daiichi Sankyo is far less than what Ranbaxy paid to acquire 46 percent of its equity a year ago

You may also be interested in...



India's Zenotech Ups Noise Against Daiichi Sankyo; Demands $20 Million In Damages

MUMBAI - The founders of India's emerging oncology and biologics company Zenotech Labs have alleged that Japanese firm Daiichi Sankyo - which holds a 47 percent equity stake in the company - destroyed the value of the company besides delaying clinical trials of one of its key oncology drugs and claiming Zenotech's product trademarks as its own. Zenotech has claimed $20 million in damages from Daiichi Sankyo at an Indian court of law

India's Zenotech Ups Noise Against Daiichi Sankyo; Demands $20 Million In Damages

MUMBAI - The founders of India's emerging oncology and biologics company Zenotech Labs have alleged that Japanese firm Daiichi Sankyo - which holds a 47 percent equity stake in the company - destroyed the value of the company besides delaying clinical trials of one of its key oncology drugs and claiming Zenotech's product trademarks as its own. Zenotech has claimed $20 million in damages from Daiichi Sankyo at an Indian court of law

Daiichi Sankyo Records ¥354 Billion Valuation Loss From Price Drop In Ranbaxy Shares

Daiichi Sankyo announced Jan. 5 a valuation loss of ¥354 billion for the fiscal quarter ending Dec. 31; the loss is associated with a more than 50 percent price drop in Ranbaxy shares the company acquired. With the loss, it is viewed that the company will report a loss in consolidated profit for the fiscal year ending March 31. Daiichi has previously estimated ¥65 billion in profit. It will be the first loss for the company since the merger of Daiichi and Sankyo in 2005. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel